Category: Chronic Pulmonary Disorders

Chronic Pulmonary Disorders

American Lung Association Launches COPD Management Program

American Lung Association is launching a new initiative to help the more than 16 million people in the US living with COPD manage symptoms and improve quality of life.

Chronic Pulmonary Disorders

Comorbid Bronchiectasis + Diabetes Tied to Worse Outcomes

A large-scale international study found that comorbid bronchiectasis and diabetes is associated with higher mortality, increased hospitalizations, and more frequent exacerbations.

Chronic Pulmonary Disorders

ENA Respiratory Secures Two US Patents for COPD Therapy

ENA Respiratory received notices of allowance for two US patents covering its innate immune modulators and their application in preventing COPD exacerbations.

Asthma

8 Recommendations for Asthma Patient Education

This article will provide 8 recommendations for effective patient education regarding inhaled medications used in treating/preventing asthma symptoms and flare-ups.

COPD

Nebulized Dual Bronchodilator Aero-007 Improved COPD Lung Function

AERO-007 demonstrated significant lung function improvements over 24 hours in patients with moderate-to-severe COPD.

Cystic fibrosis

Cystic Fibrosis Patient Receives Quadruple Transplant

A 28-year-old cystic fibrosis patient underwent a 36-hour quadruple organ transplant for both lungs, a liver, and a kidney from a single donor.

Pulmonary Fibrosis

Nebulized Treprostinil Preserved IPF Lung Function

Phase 3 trial results show significant reductions in clinical worsening and acute exacerbations for patients with idiopathic pulmonary fibrosis (IPF).

Allergies

Microplastics May Intensify Immune Response to Common Allergens

New research suggests that microplastic particles can bind to allergens and carry them deeper into the respiratory system.

Other Chronic Diseases

Long-Term Data for Recurrent Respiratory Papillomatosis Therapy

Updated clinical data demonstrates that Papzimeos for adults with Recurrent Respiratory Papillomatosis (RRP) can maintain complete responses for more than four years.